By Shawn Elliott, CFO | High Rock Accounting
In a previous life, I ran the financial operations of a specialty pharmacy that we built from zero to $50 million in revenue before private equity came in and bought us out. Before that, I spent five and a half years at another specialty pharmacy that grew from $50 million to $500 million before its own PE exit. Both of those businesses involved navigating an enormous amount of regulatory complexity, including state pharmacy permits across roughly 40 states, DEA compliance, sterile compounding standards, USP 797 and 800, and the kind of FDA scrutiny that can change your operating model on a Tuesday.
I bring all of that up because when I look at what has happened in the peptide compounding and nutraceutical space over the last 18 months, the pattern feels very familiar. The regulatory pendulum has been swinging hard. GLP-1s came off the FDA shortage list. Category 2 of the 503A bulks list has been a moving target. Twelve peptides got pulled off of Category 2 in April of 2026, with a Pharmacy Compounding Advisory Committee review scheduled for July 23 and 24 of this year that will determine the next chapter.
The clinical and operational stories around all of this have gotten a lot of coverage. What has not gotten enough coverage is the accounting story. When the FDA restricts a peptide category, the fallout is not just operational. It hits your balance sheet in ways most operators do not anticipate, and the GAAP rules around how you have to recognize that hit are not friendly. So let me walk through what is actually happening on the financial side, what the GAAP treatment looks like, and how a peptide business needs to be thinking about its books in this type of regulatory environment.
The Regulatory Whipsaw, Briefly
Just to give you some idea of where the field stands today. The big GLP-1 story is that tirzepatide came off the FDA drug shortage list in October of 2024, and semaglutide followed in early 2025. For 503B outsourcing facilities, the deadlines to stop compounding were earlier in 2025, and 503A pharmacies lost their shortage-exemption rights around the same window.
In April of 2026, the FDA went further and proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely, on the basis that clinical need for bulk-compounded versions no longer exists.
On the broader peptide side, FDA had moved roughly a dozen popular peptides into Category 2 of the interim 503A bulks list back in September of 2023, which effectively prohibited compounding those substances. Then in April of 2026, FDA removed 12 of those peptides from Category 2 and scheduled seven of them for PCAC review in July of 2026, including BPC-157, KPV, TB-500, MOTS-C, DSIP, Semax, and Epitalon, with five more (GHK-Cu, Melanotan II, LL-37, Dihexa, and PEG-MGF) up for a second hearing before February of 2027.
Important detail that operators sometimes miss. Removal from Category 2 is not the same thing as authorization to compound. It puts the substance into a transitional regulatory phase, and pharmacies still cannot legally compound those peptides until FDA goes through formal rulemaking to add them to the Category 1 bulks list. The PCAC vote itself is advisory and non-binding, which means the FDA can land somewhere different than what PCAC recommends.
So the picture today is a peptide business that may have several SKUs in active regulatory limbo, a couple that have been clearly restricted, a couple that may or may not get cleared in the back half of the year, and an inventory position that has to be valued, presented on the balance sheet, and disclosed against all of that uncertainty.
The First Hit Is Inventory
When the FDA restricts a substance and your business is sitting on bulk drug substance, intermediate product, or finished compounded inventory tied to that substance, you have an immediate inventory valuation question to answer. Under ASC 330, inventory has to be carried at the lower of cost and net realizable value, where net realizable value is the estimated selling price in the ordinary course of business minus reasonably predictable costs of completion, disposal, and transportation.
When a regulatory restriction takes a product out of your legal sales pipeline, the net realizable value of that inventory drops, often to zero or close to it. You may still have cost sitting in the inventory account that represents the API you purchased, the labor that went into compounding, the vials, the labels, and the overhead allocations. None of that matters from a GAAP perspective once you cannot legally sell the finished product. You take the write-down, you recognize the loss in the period in which the evidence supports it, and your inventory is restated at the more conservative number.
Here is the painful part. Under ASC 330 and U.S. GAAP more broadly, an inventory write-down is permanent. The codification does not allow you to write the inventory back up if conditions change later. So if you take a $400,000 write-down on a peptide inventory in Q2 because the FDA restriction makes it unsellable, and then later in the year that peptide gets cleared back onto the Category 1 bulks list and you actually could have sold it, you do not get to reverse the write-down on your GAAP books. The loss has been recognized. Any future sale of that inventory shows up as nearly all margin, which inflates gross margin in the period of sale, but the original P&L hit stays where it was.
In that type of scenario, the timing and documentation of the write-down really matter. You want to be able to show your auditor and your tax accountant exactly what FDA action triggered the valuation analysis, what your net realizable value methodology was, what specific inventory lots and quantities were affected, and what the underlying support looks like. If you do this casually or without documentation, you will be doing it again under audit with a lot more friction.
The Second Hit Is the Compliance and Pivot Spend
After the inventory hit, the next wave of accounting events is everything you have to spend to actually navigate the restriction. The legal fees to interpret what you can and cannot do under the new rules. The communications spend to alert your patient base and your prescriber network. The cost of returning or destroying restricted inventory under USP and DEA-compliant disposal procedures, where applicable. The cost of any voluntary recall, if it gets to that. The cost of new SOPs and policy updates inside your pharmacy management system.
Most of those costs are immediately expensed as period costs under the matching principle. They do not create future economic benefit in any defensible way, so they hit the P&L in the period incurred.
Where it gets a bit more nuanced is the revenue model pivot costs. If your business is pivoting from compounded peptide sales to distribution of FDA-approved branded products, or from one peptide SKU mix to a different SKU mix that requires new sourcing relationships, new labeling, new training, or new patient acquisition spend, you have to think carefully about what is a capitalizable cost and what is a period cost. New systems implementations might be capitalizable as software. Reusable training content might be capitalizable as an intangible. Pure marketing spend to reposition the brand is period cost. The treatment is not always intuitive, and the documentation has to be tight, because this is the type of area where auditors push back.
The Third Hit Is Revenue Concentration Risk
A lot of peptide businesses built up over the past three or four years are heavily concentrated in one or two SKUs. Semaglutide compounding alone became a massive line of business for hundreds of pharmacies and telehealth-pharmacy operators between 2022 and early 2025. When tirzepatide came off the shortage list in October of 2024 and semaglutide followed in early 2025, businesses that were 70 or 80% concentrated in GLP-1 compounding suddenly had a financial planning problem that was not solvable by tightening the chart of accounts.
The accounting implication is twofold. First, your revenue concentration is now something you need to disclose and discuss in your financial statements and any investor or lender reporting you do. Second, you need to start building proper revenue segmentation in your chart of accounts so that you can see your concentration risk in real time. A peptide business that cannot tell me what percentage of its trailing 12-month revenue comes from any one SKU is a peptide business that cannot make smart pivots when the next FDA action drops, and I have seen that movie play out the hard way more than once.
From a sales tax perspective, depending on your structure and your states of operation, a sudden pivot from prescription compounded products into branded distribution or into consumer-direct nutraceutical products can also change your sales tax obligations and your nexus footprint. Compounded prescriptions and FDA-approved drugs are generally exempt in most states. Many over-the-counter nutraceuticals are not. This is the kind of thing you want your accountant looking at before the pivot, not three quarters later when a state notice arrives in the mail.
Reserves, Disclosures, and the Path Through PCAC
With the July 2026 PCAC review on the calendar and a second review queued before February 2027, the prudent peptide operator is going to have to do some forecasting around outcomes that are genuinely uncertain. ASC 450 governs how you handle loss contingencies, and the framework is straightforward. A loss is recognized if it is probable and reasonably estimable. A loss is disclosed but not recognized if it is reasonably possible but not yet probable, or if it is probable but not reasonably estimable. If the chance of loss is remote, no disclosure is required.
What this means in practice for a peptide business is that for any SKU sitting in active PCAC review, you should be running a periodic assessment of the regulatory probabilities, the inventory exposure tied to each substance, and the potential financial impact under both outcomes. That assessment becomes the support file for your loss contingency accounting, and the same file becomes the basis for any footnote disclosure in your financial statements. If you are venture-backed or carrying any kind of credit facility, your lenders and investors will expect to see this analysis, and they will ask sharper questions if it is not already on the page.
On the reserve side, depending on materiality, you may also want to be building an inventory obsolescence reserve as a contra-asset rather than waiting to take a single large write-down when an FDA action lands. The reserve approach smooths the P&L volatility and gives you a more honest balance sheet on any given month-end. The reserve estimate ties to your forecast of FDA actions, your historical write-down patterns, and your turn rate by SKU. Your accountant should be able to help you build a defensible reserve methodology so you are not making the call up under pressure when the news breaks.
The Game Plan
If you are running a peptide business right now, here is the order I would put things in.
First, get your chart of accounts segmented properly. Every peptide SKU should be its own revenue line, its own inventory line, and its own cost-of-goods line. If your books are giving you one undifferentiated revenue number for “compounded products” or “peptide sales,” you cannot manage concentration risk, you cannot react cleanly to FDA actions, and you cannot tell a clean story to lenders or investors. This is the foundation, and it has to be solid before anything else gets built on top of it.
Second, build a regulatory tracker that ties to your inventory and your revenue. For every SKU you sell, you should know what bulks list it sits on, what category, when the last FDA action affected it, what your inventory exposure is in dollars, and what your trailing 12-month revenue is. This tracker is a living document. It updates with every FDA action, and it drives your write-down and disclosure decisions in real time.
Third, get your accounting system fit for purpose. Most peptide compounders we see are either running on Xero with strong inventory bolt-ons or on Sage Intacct if the volume and complexity justify the step up. Either of those is a defensible modern stack. Pair it with Brex or Ramp for spend management and Gusto, Rippling, ADP, or Paychex for payroll, and you have the foundation for clean monthly close and audit-ready books. The accounting platform decision is one of those things you want to get right before scale, not in the middle of a pivot.
Fourth, document everything. The FDA regulatory environment in this space is going to keep moving, and every write-down, every reserve estimate, every disclosure footnote, and every pivot cost decision needs to have the support attached in the system so you can follow the breadcrumbs later. We tell our clients to attach the FDA notice, the legal memo, the inventory listing, and the journal entry support all in the same place, every time. When an auditor or a diligence team comes asking, you hand it over on a silver platter.
Fifth, do a sanity check at every monthly close. Are your write-downs proportionate to the exposure. Are your reserves built on a methodology you can defend. Is your revenue segmentation telling you the same concentration story as your operational view of the business. The monthly close is where issues either get caught early or quietly compound until they show up in audit or diligence as a much bigger problem.
Running a peptide business in this regulatory environment is a real challenge, and the operators doing it well are the ones who treat the accounting as a strategic function rather than an afterthought. The regulatory shifts are going to keep coming. The financial impact is going to keep showing up on the balance sheet. The businesses that win are the ones with squeaky clean books and a CFO function that can pivot as fast as the FDA can publish a Federal Register notice. If you want a second set of eyes on where your books are today, we are just a Slack message away.
Two Easy Ways to Get a Second Set of Eyes on This
Hawaiian Shirt Friday: Ask an Accountant Hour meets every Friday at 10AM Pacific Time, open Zoom, no appointment needed. Bring your inventory valuation questions, your reserve methodology, or whatever else the FDA has thrown at you this month. Join here: https://us02web.zoom.us/j/88992505122?pwd=LdbL4NYxN2NNk5RanaHRVtrHgT43O9.1
Prefer a one-on-one conversation? Grab a 30-minute slot on my calendar to walk through your specific situation: https://meetings-na2.hubspot.com/shawn-elliott/30-minute-meeting
Sources
1. PeptideClarity, “Peptide FDA Regulatory Tracker: PCAC, 503A/503B Status” (April 2026): documents the April 22, 2026 removal of BPC-157 and 11 other peptides from Category 2, and the PCAC review schedule for seven peptides (BPC-157, KPV, TB-500, MOTS-C, DSIP, Semax, Epitalon) on July 23-24, 2026, with five additional peptides queued for a second hearing before February 2027. getpeptideclarity.com/regulatory.
2. Hyman, Phelps & McNamara (FDA Law Blog), “FDA’s Pep(tide) Rally! What Compounders and Industry Need to Know” (April 2026): coverage of the April 16, 2026 Federal Register notice (Docket No. FDA-2025-N-6895) announcing the July 2026 PCAC meeting and the substances under review. thefdalawblog.com.
3. Harris Beach Murtha, “GLP-1 Weight-Loss Drugs Off Shortage List; Deadlines to Stop Compounding” (June 2025): tirzepatide removed from FDA shortage list December 19, 2024; FDA received over 455 adverse event reports tied to compounded semaglutide and over 320 tied to compounded tirzepatide as of February 28, 2025. harrisbeachmurtha.com.
4. Loti Labs / Healthfacts Journal coverage of the April 30, 2026 FDA proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facilities bulks list, citing resolved commercial shortages and absence of clinical need for bulk-compounded versions. lotilabs.com / healthfactsjournal.com.
5. Newtropin / Lexology (Foley & Lardner), “FDA removes certain peptide bulk drug substances from Category 2 of interim 503A bulks list” (Sept-Oct 2024 plus April 2026 update): explains the Category 1 / Category 2 / Category 3 framework, the meaning of removal from Category 2 (transitional phase, not authorization to compound), and the PCAC advisory and non-binding role. lexology.com / newtropin.com.
6. FASB ASC 330-10-35-1B and ASU 2015-11 (Inventory, Topic 330): requires inventory measured under FIFO or average cost to be carried at the lower of cost and net realizable value, with loss recognized in the period when evidence supports it. CPA Journal coverage at cpajournal.com.
7. Houseblend, “ASC 330 Inventory Valuation: Write-Downs and Reversals” (Feb 2026): U.S. GAAP does not permit reversal of inventory write-downs to NRV; the codification enforces a one-way conservatism rule. houseblend.io.
Enjoyed this article? Consider Sharing
Author
